StockData
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc. (ALLR) stock

ALLRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.84−0.03 (-3.91%)

Close on Nov 17, 2026Market cap $13.38MP/E –Yield –

Allarity Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Allarity Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.52M, down 16.3% year over year. For fiscal 2025 it was $6.60M, up 8.3% from the year before. The highest annual figure on record is $14.20M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.60M+8.3%
FY2024Dec 31, 2024$6.10M-14.2%
FY2023Dec 31, 2023$7.10M+2.5%
FY2022Dec 31, 2022$6.93M-51.2%
FY2021Dec 31, 2021$14.20M+236.6%
FY2020Dec 31, 2020$4.22M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.35M-42.1%
Q1 FY2026Mar 31, 2026$1.30M-7.6%
Q4 FY2025Dec 31, 2025$1.67M-9.4%
Q3 FY2025Sep 30, 2025$1.20M+17.8%
Q2 FY2025Jun 30, 2025$2.32M+119.4%
Q1 FY2025Mar 31, 2025$1.40M-35.3%
Q4 FY2024Dec 31, 2024$1.85M-29.6%
Q3 FY2024Sep 30, 2024$1.02M-47.6%
Q2 FY2024Jun 30, 2024$1.06M+12.4%
Q1 FY2024Mar 31, 2024$2.17M-27.8%
Q4 FY2023Dec 31, 2023$2.62M+54.7%
Q3 FY2023Sep 30, 2023$1.95M+51.1%
Q4 FY2022Dec 31, 2022$941.00K-90.1%
Q3 FY2022Sep 30, 2022$3.00M+121.7%
Q2 FY2022Jun 30, 2022$1.70M-25.6%
Q1 FY2022Mar 31, 2022$1.29M+3.0%
Q4 FY2021Dec 31, 2021$9.52M+471.5%
Q3 FY2021Sep 30, 2021$1.36M+72.6%
Q2 FY2021Jun 30, 2021$2.28M–
Q1 FY2021Mar 31, 2021$1.25M–
Q4 FY2020Dec 31, 2020$1.67M–
Q3 FY2020Sep 30, 2020$785.00K–

More Allarity Therapeutics figures

See a number that looks wrong?